卡培他滨单药治疗老年大肠癌的疗效和安全性

Efficacy and safety of capecitabine in treatment of colorectal cancer

目的探讨卡培他滨单药治疗老年大肠癌的疗效和安全性。方法收集我院160例Ⅳ期结直肠癌老年患者,完成一线联合化疗后,80例给予卡培他滨单药维持(维持组),另80例无后续治疗(对照组)。Kaplan-Meier曲线做生存分析;比较两组的治疗有效率;比较维持组服用卡培他滨期间与联合化疗期间的不良反应发生率;比较维持组服用卡培他滨期间与同期对照组的不良反应发生率。结果(1)Kaplan-Meier曲线提示,维持组中位PFS高于对照组(P<0.05)。(2)维持组的有效率高于对照组(P<0.05)。⑶维持组服用卡培他滨期间各种不良反应的发生率与联合化疗期间相比均较低(P<0.05)。⑷维持组服用卡培他滨期间与同期对照组的不良反应发生率相比差异均无显著性(P>0.05)。结论老年结直肠癌患者在联合化疗后采用卡培他滨单药维持较无维持患者具有较长的中位PFS和相似的不良反应发生率,值得临床推广。

Objective To investigate the efficacy and safety of capecitabine in the treatment of colorectal cancer. Methods Totally 160 elderly patients with stage 1V colorectal cancer were enrolled in this study. After first -line combined chemotherapy, 80 patients were treated with capecitabine monotherapy （maintenance group） and another 80 cases were not （control group）. The survival rate was analyzed by Kaplan-Meier curve and the efficiency and incidence of adverse events were compared. Results （ 1 ） The Kaplan-Meier curve suggested that the difference between two groups was statistically significant （P 〈 0.05）. （2）The response rate of maintenance group was significantly higher than that of control group （P 〈 0.05）. （3） The incidence of adverse events during capecitabine monotherapy was lower than that during combined chemotherapy （P 〈 0.05 ）. （4）The incidence of adverse reactions during capecitabine monotherapy was similar to that of control group （P 〉 0.05 ）. Conclusion Capecitabine monotherapy in patients with stage IV colorectal cancer after combined chemotherapy has a longer median PFS than those without maintenance but similar adverse reactions, which was worthy of clinical promotion.